Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RPC1063 phase 2 induction and maintenance study in moderately to severely active ulcerative colitis
NL-OMON47857Phase 2Active, not recruiting
- Sponsor
- Celgene Corporation
- Start
- Jul 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ozanimod in autoimmune colitis (3 arms), sponsored by Celgene Corporation. Primary endpoint: Clinical remission at Week 8. Started Jul 2014; status: active, not recruiting.
02
Drugs
ozanimod
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on NL-OMON47857.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47857.